Cite
Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
MLA
Patrikidou, Anna, et al. “Long-Term Outcome of Molecular Subgroups of GIST Patients Treated with Standard-Dose Imatinib in the BFR14 Trial of the French Sarcoma Group.” European Journal of Cancer, vol. 52, Jan. 2016, pp. 173–80. EBSCOhost, https://doi.org/10.1016/j.ejca.2015.10.069.
APA
Patrikidou, A., Domont, J., Chabaud, S., Ray-Coquard, I., Coindre, J.-M., Bui-Nguyen, B., Adenis, A., Rios, M., Bertucci, F., Duffaud, F., Chevreau, C., Cupissol, D., Pérol, D., Emile, J.-F., Blay, J.-Y., & Cesne, A. L. (2016). Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. European Journal of Cancer, 52, 173–180. https://doi.org/10.1016/j.ejca.2015.10.069
Chicago
Patrikidou, Anna, Julien Domont, Sylvie Chabaud, Isabelle Ray-Coquard, Jean-Michel Coindre, Binh Bui-Nguyen, Antoine Adenis, et al. 2016. “Long-Term Outcome of Molecular Subgroups of GIST Patients Treated with Standard-Dose Imatinib in the BFR14 Trial of the French Sarcoma Group.” European Journal of Cancer 52 (January): 173–80. doi:10.1016/j.ejca.2015.10.069.